



FOR IMMEDIATE RELEASE

Metactive Closes \$2 Million of Additional Series A Financing and Appoints David Ferrera to the Board of Directors

OLATHE, Kan. – Feb. 23, 2015 – [Metactive Medical Inc.](#) (Metactive), an early-stage company focused on developing embolization devices for the treatment of peripheral vascular and neurovascular diseases, today announced that it has closed on \$2 million of additional Series A financing, led by the Kansas Bioscience Authority (KBA), an existing Metactive investor. Proceeds will be used to continue the development of Metactive’s novel embolic devices for occlusion of saccular aneurysms and peripheral arteries and veins. Metactive previously raised \$5 million in Series A funding, bringing the total funding raised to date to \$7 million.

“Metactive has shown immediate, complete and lasting occlusion of large saccular aneurysms with rapid endothelialization of the aneurysm neck in a challenging nonclinical model, as well as similarly robust performance with a peripheral occlusion device,” said Tom Krol, Managing Director at KBA and a member of Metactive’s board of directors. “Clinicians treat thousands of saccular aneurysms and peripheral arteries and veins each year. We believe that Metactive’s devices have the potential to be better for patients, faster and easier for physicians to use, and less expensive for payers.”

Metactive also announced today the appointment of David Ferrera to its board of directors. Ferrera is currently President and Chief Technology Officer of Blockade Medical and has 20 years of leadership experience in the medical device industry at several market-leading neurovascular firms, including MindFrame, Microvention and Micrus Endovascular.

“I am pleased to have the resources to accelerate the development of our novel, potentially life-saving products and to welcome David to our board to help us realize our goal of providing physicians faster, better and less expensive options for vascular occlusion,” said F. Nicholas Franano, MD, President and CEO of Metactive.

About Peripheral Artery and Aneurysm Embolization

Embolization is a minimally invasive treatment that blocks the flow of blood in selected segments of arteries and veins, enabling physicians to divert blood away from cancerous tumors and other abnormal tissues, as well as from damaged or malformed segments of blood vessels. More than 150,000 peripheral vascular embolization procedures are performed each year worldwide using coils and vascular plugs. Similarly, more than 150,000 cerebral aneurysm embolization procedures are performed worldwide each year using coils and flow-diverting vascular stents. There is currently a need in these markets for endovascular embolization devices that can be placed quickly and easily, with a high degree of precision, and that result in immediate and lasting occlusion.

About Metactive Medical

Metactive is developing novel endovascular medical devices for the treatment of neurovascular and peripheral vascular diseases. Metactive’s first products enable precise and immediate occlusion and rapid sealing of cerebral aneurysms and other target vessel segments using an over-the-wire microcatheter platform. For more information, please visit www.metactivemedical.com.

Company Contact:

F. Nicholas Franano, MD, President and CEO
Metactive Medical Inc.
(816) 550-9177
nfranano@metactivemedical.com

Media Contact:

Kari Watson
MacDougall Biomedical Communications
781-235-3060
kwatson@macbiocom.com

###